Skip to main content

Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis

  • Ymkje Anna de Vries (a1), Annelieke M. Roest (a2), Elisabeth H. Bos (a1), Johannes G. M. Burgerhof (a3), Hanna M. van Loo (a4) and Peter de Jonge (a2)...

Improvement in depression within the first 2 weeks of antidepressant treatment predicts good outcomes, but non-improvers can still respond or remit, whereas improvers often do not.


We aimed to investigate whether early improvement of individual depressive symptoms better predicts response or remission.


We obtained individual patient data of 30 trials comprising 2184 placebo-treated and 6058 antidepressant-treated participants. Primary outcome was week 6 response; secondary outcomes were week 6 remission and week 12 response and remission. We compared models that only included improvement in total score by week 2 (total improvement model) with models that also included improvement in individual symptoms.


For week 6 response, the area under the receiver operating characteristic curve and negative and positive predictive values of the total improvement model were 0.73, 0.67 and 0.74 compared with 0.77, 0.70 and 0.71 for the item improvement model. Model performance decreased for week 12 outcomes. Of predicted non-responders, 29% actually did respond by week 6 and 43% by week 12, which was decreased from the baseline (overall) probabilities of 51% by week 6 and 69% by week 12. In post hoc analyses with continuous rather than dichotomous early improvement, including individual items did not enhance model performance.


Examining individual symptoms adds little to the predictive ability of early improvement. Additionally, early non-improvement does not rule out response or remission, particularly after 12 rather than 6 weeks. Therefore, our findings suggest that routinely adapting pharmacological treatment because of limited early improvement would often be premature.

Declaration of interest


Corresponding author
Correspondence: Ymkje Anna de Vries, Department of Psychology, University of Groningen, Grote Kruisstraat 2/1, 9712 TS, Groningen, the Netherlands. Email:
Hide All
1National Institute for Health and Care Excellence. Depression: The NICE Guideline on the Treatment and Management of Depression in Adults (CG90). NICE, 2010.
2Spijker, J, Bockting, CLH, Meeuwissen, JAC, van Vliet, IM, Emmelkamp, PMG, Hermens, MLM, et al. Multidisciplinaire richtlijn Depressie (Derde revisie) : Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een depressieve stoornis. Trimbos-Instituut, 2013.
3American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. American Psychiatric Association, 2010.
4Undurraga, J, Baldessarini, RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012; 37: 851–64.
5Taylor, MJ, Freemantle, N, Geddes, JR, Bhagwagar, Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: a systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63: 1217–23.
6Stassen, HH, Angst, J, Hell, D, Scharfetter, C, Szegedi, A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68: 1195–205.
7Szegedi, A, Jansen, WT, Van Willigenburg, APP, Van Der Meulen, E, Stassen, HH, Thase, ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70: 344–53.
8Uher, R, Mors, O, Rietschel, M, Rajewska-Rager, A, Petrovic, A, Zobel, A, et al. Early and delayed onset of response to antidepressants in individual trajectories of change during treatment of major depression: a secondary analysis of data from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. J Clin Psychiatry 2011; 72: 1478–84.
9Gorwood, P, Bayle, F, Vaiva, G, Courtet, P, Corruble, E, Llorca, P-M. Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis. Eur Psychiatry 2013; 28: 362–71.
10Wagner, S, Engel, A, Engelmann, J, Herzog, D, Dreimüller, N, Müller, MB, et al. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: systematic review and meta-analysis. J Psychiatr Res 2017; 94: 96106.
11Fried, EI, Nesse, RM. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Med 2015; 13: 72.
12Uher, R, Perlis, RH, Henigsberg, N, Zobel, A, Rietschel, M, Mors, O, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012; 42: 967–80.
13Chekroud, AM, Zotti, RJ, Shehzad, Z, Gueorguieva, R, Johnson, MK, Trivedi, MH, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 2016; 3: 243–50.
14Tokuoka, H, Takahashi, H, Ozeki, A, Kuga, A, Yoshikawa, A, Tsuji, T, et al. Trajectories of depression symptom improvement and associated predictor analysis: an analysis of duloxetine in double-blind placebo-controlled trials. J Affect Disord 2016; 196: 171–80.
15Funaki, K, Nakajima, S, Suzuki, T, Mimura, M, Uchida, H. Early improvements in individual symptoms to predict later remission in major depressive disorder treated with mirtazapine. J Clin Pharmacol 2016; 56: 1111–9.
16Sakurai, H, Uchida, H, Abe, T, Nakajima, S, Suzuki, T, Pollock, BG, et al. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord 2013; 151: 506–13.
17Mizushima, J, Uchida, H, Tada, M, Suzuki, T, Mimura, M, Nio, S. Early improvement of specific symptoms predicts subsequent recovery in bipolar depression. J Clin Psychiatry 2017; 78: e14651.
18Berlin, I, Lavergne, F. Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. Eur Psychiatry 1998; 13: 138–42.
19Farabaugh, AH, Bitran, S, Witte, J, Alpert, J, Chuzi, S, Clain, AJ, et al. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol 2010; 25: 214–7.
20Clinical Study Data Request (CSDR). CSDR, 2018 (
21Leucht, S, Fennema, H, Engel, R, Kaspers-Janssen, M, Lepping, P, Szegedi, A. What does the HAMD mean? J Affect Disord 2013; 148: 243–8.
22Cipriani, A, Furukawa, TA, Salanti, G, Chaimani, A, Atkinson, LZ, Ogawa, Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391(10128): 1357–66.
23Tibshirani, R. Regression selection and shrinkage via the lasso. J R Stat Soc B 1996; 58: 267–88.
24Friedman, J, Hastie, T, Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010; 33: 122.
25Posternak, MA, Baer, L, Nierenberg, AA, Fava, M. Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry 2011; 72: 949–54.
26Bschor, T, Kern, H, Henssler, J, Baethge, C. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry 2018; 79(1): 16r10749.
27Ruhé, HG, Huyser, J, Swinkels, JA, Schene, AH. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder - systematic review. Br J Psychiatry 2006; 189: 309–16.
28Dold, M, Bartova, L, Rupprecht, R, Kasper, S. Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials. Psychother Psychosom 2017; 86: 283–91.
29Ueno, F, Nakajima, S, Suzuki, T, Abe, T, Sato, Y, Mimura, M, et al. Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression. J Clin Psychiatry 2015; 76: 434–9.
30Hieronymus, F, Nilsson, S, Eriksson, E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry 2016; 6: e834.
31Zhou, X, Ravindran A, V, Qin, B, Del Giovane, C, Li, Q, Bauer, M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression. J Clin Psychiatry 2015; 76: e48798.
32Adli, M, Baethge, C, Heinz, A, Langlitz, N, Bauer, M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387400.
33Jakubovski, E, Varigonda, AL, Freemantle, N, Taylor, MJ, Bloch, MH. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2015; 54: 557–64.
34Wisniewski, SR, Rush, AJ, Nierenberg, AA, Gaynes, BN, Warden, D, Luther, JF, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009; 166: 599607.
35Gullion, CM, Rush, AJ. Toward a generalizable model of symptoms in major depressive disorder. Biol Psychiatry 1998; 44: 959–72.
36Uher, R, Perlis, RH, Placentino, A, Dernovšek, MZ, Henigsberg, N, Mors, O, et al. Self-report and clinician-rated measures of depression severity: can one replace the other? Depress Anxiety 2012; 29: 1043–9.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary materials

de Vries et al. supplementary material
de Vries et al. supplementary materia 1

 Word (4.9 MB)
4.9 MB


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis

  • Ymkje Anna de Vries (a1), Annelieke M. Roest (a2), Elisabeth H. Bos (a1), Johannes G. M. Burgerhof (a3), Hanna M. van Loo (a4) and Peter de Jonge (a2)...
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *